Cyclosporine induces cancer progression by a cell-autonomous mechanism

Minoru Hojo, Takashi Morimoto, Mary Maluccio, Tomohiko Asano, Kengo Morimoto, Milagros Lagman, Toshikazu Shimbo, Manikkam Suthanthiran

Research output: Contribution to journalArticle

859 Citations (Scopus)

Abstract

Malignancy is a common and dreaded complication following organ transplantation. The high incidence of neoplasm and its aggressive progression, which are associated with immunosuppressive therapy, are thought to be due to the resulting impairment of the organ recipient's immune- surveillance system. Here we report a mechanism for the heightened malignancy that is independent of host immunity. We show that cyclosporine (cyclosporin A), an immunosuppressant that has had a major impact on improving patient outcome following organ transplantation, induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. Our studies show that cyclosporine treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. These changes are prevented by treatment with monoclonal antibodies directed at transforming growth factor- β (TGF-β). In vivo, cyclosporine enhances tumour growth in immunodeficient SCID-beige mice; anti-TGF-β monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases. Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF-β production is involved in this.

Original languageEnglish (US)
Pages (from-to)530-534
Number of pages5
JournalNature
Volume397
Issue number6719
DOIs
StatePublished - Feb 11 1999
Externally publishedYes

Fingerprint

Cyclosporine
Transforming Growth Factors
Immunosuppressive Agents
Neoplasms
Organ Transplantation
Monoclonal Antibodies
SCID Mice
Growth
Cell Movement
Immune System
Immunity
Adenocarcinoma
Therapeutics
Neoplasm Metastasis
Membranes
Antibodies
Incidence

ASJC Scopus subject areas

  • General

Cite this

Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., ... Suthanthiran, M. (1999). Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature, 397(6719), 530-534. https://doi.org/10.1038/17401

Cyclosporine induces cancer progression by a cell-autonomous mechanism. / Hojo, Minoru; Morimoto, Takashi; Maluccio, Mary; Asano, Tomohiko; Morimoto, Kengo; Lagman, Milagros; Shimbo, Toshikazu; Suthanthiran, Manikkam.

In: Nature, Vol. 397, No. 6719, 11.02.1999, p. 530-534.

Research output: Contribution to journalArticle

Hojo, M, Morimoto, T, Maluccio, M, Asano, T, Morimoto, K, Lagman, M, Shimbo, T & Suthanthiran, M 1999, 'Cyclosporine induces cancer progression by a cell-autonomous mechanism', Nature, vol. 397, no. 6719, pp. 530-534. https://doi.org/10.1038/17401
Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999 Feb 11;397(6719):530-534. https://doi.org/10.1038/17401
Hojo, Minoru ; Morimoto, Takashi ; Maluccio, Mary ; Asano, Tomohiko ; Morimoto, Kengo ; Lagman, Milagros ; Shimbo, Toshikazu ; Suthanthiran, Manikkam. / Cyclosporine induces cancer progression by a cell-autonomous mechanism. In: Nature. 1999 ; Vol. 397, No. 6719. pp. 530-534.
@article{2c694346a5e0412e9ceed817a2b8ccc4,
title = "Cyclosporine induces cancer progression by a cell-autonomous mechanism",
abstract = "Malignancy is a common and dreaded complication following organ transplantation. The high incidence of neoplasm and its aggressive progression, which are associated with immunosuppressive therapy, are thought to be due to the resulting impairment of the organ recipient's immune- surveillance system. Here we report a mechanism for the heightened malignancy that is independent of host immunity. We show that cyclosporine (cyclosporin A), an immunosuppressant that has had a major impact on improving patient outcome following organ transplantation, induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. Our studies show that cyclosporine treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. These changes are prevented by treatment with monoclonal antibodies directed at transforming growth factor- β (TGF-β). In vivo, cyclosporine enhances tumour growth in immunodeficient SCID-beige mice; anti-TGF-β monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases. Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF-β production is involved in this.",
author = "Minoru Hojo and Takashi Morimoto and Mary Maluccio and Tomohiko Asano and Kengo Morimoto and Milagros Lagman and Toshikazu Shimbo and Manikkam Suthanthiran",
year = "1999",
month = "2",
day = "11",
doi = "10.1038/17401",
language = "English (US)",
volume = "397",
pages = "530--534",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6719",

}

TY - JOUR

T1 - Cyclosporine induces cancer progression by a cell-autonomous mechanism

AU - Hojo, Minoru

AU - Morimoto, Takashi

AU - Maluccio, Mary

AU - Asano, Tomohiko

AU - Morimoto, Kengo

AU - Lagman, Milagros

AU - Shimbo, Toshikazu

AU - Suthanthiran, Manikkam

PY - 1999/2/11

Y1 - 1999/2/11

N2 - Malignancy is a common and dreaded complication following organ transplantation. The high incidence of neoplasm and its aggressive progression, which are associated with immunosuppressive therapy, are thought to be due to the resulting impairment of the organ recipient's immune- surveillance system. Here we report a mechanism for the heightened malignancy that is independent of host immunity. We show that cyclosporine (cyclosporin A), an immunosuppressant that has had a major impact on improving patient outcome following organ transplantation, induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. Our studies show that cyclosporine treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. These changes are prevented by treatment with monoclonal antibodies directed at transforming growth factor- β (TGF-β). In vivo, cyclosporine enhances tumour growth in immunodeficient SCID-beige mice; anti-TGF-β monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases. Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF-β production is involved in this.

AB - Malignancy is a common and dreaded complication following organ transplantation. The high incidence of neoplasm and its aggressive progression, which are associated with immunosuppressive therapy, are thought to be due to the resulting impairment of the organ recipient's immune- surveillance system. Here we report a mechanism for the heightened malignancy that is independent of host immunity. We show that cyclosporine (cyclosporin A), an immunosuppressant that has had a major impact on improving patient outcome following organ transplantation, induces phenotypic changes, including invasiveness of non-transformed cells, by a cell-autonomous mechanism. Our studies show that cyclosporine treatment of adenocarcinoma cells results in striking morphological alterations, including membrane ruffling and numerous pseudopodial protrusions, increased cell motility, and anchorage-independent (invasive) growth. These changes are prevented by treatment with monoclonal antibodies directed at transforming growth factor- β (TGF-β). In vivo, cyclosporine enhances tumour growth in immunodeficient SCID-beige mice; anti-TGF-β monoclonal antibodies but not control antibodies prevent the cyclosporine-induced increase in the number of metastases. Our findings suggest that immunosuppressants like cyclosporine can promote cancer progression by a direct cellular effect that is independent of its effect on the host's immune cells, and that cyclosporine-induced TGF-β production is involved in this.

UR - http://www.scopus.com/inward/record.url?scp=0033545299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033545299&partnerID=8YFLogxK

U2 - 10.1038/17401

DO - 10.1038/17401

M3 - Article

C2 - 10028970

AN - SCOPUS:0033545299

VL - 397

SP - 530

EP - 534

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6719

ER -